Mounjaro®
Starting from £179.99/mo
Start journey Learn moreStopping a GLP-1 weight loss injection — whether tirzepatide or semaglutide — typically triggers a gradual return of appetite and, for many people, some regain of lost weight. Clinical trial data shows this is a predictable physiological response, not a personal failing. These are prescription-only medicines, and any decision to stop or pause should involve your prescriber. What coming off weight loss injections involves depends on your dose, how long you've been treated, and the lifestyle changes you've built alongside it.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The clearest evidence comes from the STEP 1 extension study for semaglutide and the SURMOUNT-1 follow-up for tirzepatide. In both cases, participants who stopped active treatment regained a substantial portion of their lost weight within 12 months, while those who continued maintained their results. The SURMOUNT-1 programme, involving thousands of adults treated with tirzepatide, found that weight returned toward baseline after withdrawal, the medicine was doing biological work that stopped the moment it was discontinued. How these injections produce their effects helps explain why: once the GIP and GLP-1 receptor signals fade, hunger hormones rebound and appetite regulation reverts. The STEP 1 trial data, published in the New England Journal of Medicine, is the benchmark for semaglutide; equivalent tirzepatide extension data is cited in NICE's appraisal (TA1026). Neither finding means treatment must be lifelong for everyone, but it does mean stopping is a clinical decision with real physiological consequences, not just a lifestyle choice.
The side effects of coming off weight loss injections are largely the mirror image of starting. When you begin, GI symptoms (nausea, loose stools, reflux, bloating) are most common and usually settle over a few weeks. When you stop, those same symptoms often improve or disappear, which some people find a relief. What replaces them is subtler: a gradual return of hunger, food noise (the persistent mental chatter about eating), and cravings that the medicine had quietened. The broader picture of injection side effects covers both phases. Some people also notice a dip in energy or mood in the weeks after stopping, not a recognised pharmacological withdrawal effect, but a response that prescribers hear about regularly. Fatigue and low mood after stopping are worth mentioning at your next GP appointment if they persist beyond a couple of weeks.
Most side effects of coming off weight loss injections are gradual and mild. A few warrant prompt medical attention. If you develop severe, persistent abdominal pain that spreads to your back (with or without vomiting) seek urgent help; the MHRA's January 2026 Drug Safety Update flagged acute pancreatitis as a known risk with GLP-1 medicines, and symptoms can occasionally persist or appear shortly after stopping. Rapid, unexplained weight loss after coming off treatment (rather than expected gradual regain) is also worth raising with a GP. If you notice sudden changes to your vision, the connection between weight loss injections and eyesight is something our prescribers can discuss. You can report any suspected side effect (at any point during or after treatment) through the MHRA's Yellow Card scheme; it is the UK's primary route for flagging medicine safety concerns and your report genuinely contributes to ongoing monitoring. The NHS patient information page for tirzepatide lists symptoms that require urgent attention and is worth bookmarking.
There is no pharmacological requirement to taper GLP-1 injections gradually in the way some medicines demand. That said, stopping abruptly at a high maintenance dose versus finishing a pen at 2.5mg are very different experiences. A prescriber reviewing your situation will weigh how long you've been on treatment, what dose you're at, your current weight trajectory, and whether the underlying condition that qualified you for treatment has changed. Severe or persistent side effects are sometimes the reason people want to stop, and there may be alternatives (a dose reduction, a treatment break, or switching medicine) before stopping entirely. The full range of licensed weight loss injections available in the UK means options exist. If you're thinking about this and not already under clinical review, starting a free consultation with our prescribers is the most direct route to a personalised answer rather than a generic one.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.